Equities analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report sales of $1.77 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $450,000.00 and the highest estimate coming in at $3.08 million. AVEO Pharmaceuticals reported sales of $430,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 311.6%. The firm is expected to announce its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year sales of $11.05 million for the current fiscal year, with estimates ranging from $3.11 million to $24.30 million. For the next financial year, analysts anticipate that the firm will report sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.

AVEO has been the topic of a number of analyst reports. Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. HC Wainwright reiterated a “hold” rating and issued a $1.00 price target on shares of AVEO Pharmaceuticals in a research note on Monday, March 18th. Finally, National Securities initiated coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, March 28th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $1.96.

In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was acquired at an average price of $1.14 per share, with a total value of $4,956,522.78. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of AVEO. Two Sigma Securities LLC purchased a new position in AVEO Pharmaceuticals in the 4th quarter worth about $28,000. HCR Wealth Advisors purchased a new position in AVEO Pharmaceuticals in the 1st quarter worth about $28,000. Chicago Equity Partners LLC purchased a new stake in shares of AVEO Pharmaceuticals during the 4th quarter valued at about $32,000. Albion Financial Group UT purchased a new stake in shares of AVEO Pharmaceuticals during the 4th quarter valued at about $38,000. Finally, Excalibur Management Corp increased its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 40,000 shares during the last quarter. 28.31% of the stock is owned by institutional investors and hedge funds.

AVEO Pharmaceuticals stock traded down $0.06 during mid-day trading on Wednesday, reaching $0.76. The stock had a trading volume of 2,423,600 shares, compared to its average volume of 5,789,052. The stock has a market cap of $136.63 million, a price-to-earnings ratio of -4.00 and a beta of 1.26. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: Liquidity

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.